Lawrence G. Hamel

2013

In 2013, Lawrence G. Hamel earned a total compensation of $891.5K as Chief Development Officer at AcelRx Pharmaceuticals, a 73% increase compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$124,520
Option Awards$458,346
Salary$301,000
Other$7,650
Total$891,516

Hamel received $458.3K in option awards, accounting for 51% of the total pay in 2013.

Hamel also received $124.5K in non-equity incentive plan, $301K in salary and $7.7K in other compensation.

Rankings

In 2013, Lawrence G. Hamel's compensation ranked 7,153rd out of 12,286 executives tracked by ExecPay. In other words, Hamel earned more than 41.8% of executives.

ClassificationRankingPercentile
All
7,153
out of 12,286
42nd
Division
Manufacturing
2,549
out of 4,612
45th
Major group
Chemicals And Allied Products
792
out of 1,466
46th
Industry group
Drugs
592
out of 1,160
49th
Industry
Pharmaceutical Preparations
465
out of 890
48th
Source: SEC filing on April 28, 2016.

Hamel's colleagues

We found five more compensation records of executives who worked with Lawrence G. Hamel at AcelRx Pharmaceuticals in 2013.

2013

Richard King

AcelRx Pharmaceuticals

Chief Executive Officer

2013

Pamela Palmer

AcelRx Pharmaceuticals

Chief Medical Officer

2013

David Chung

AcelRx Pharmaceuticals

Chief Commercial Officer

2013

James Welch

AcelRx Pharmaceuticals

Chief Financial Officer

2013

Badri Dasu

AcelRx Pharmaceuticals

Chief Engineering Officer

News

In-depth

You may also like